drugset / Trial / NCT00648531
Fasting Study of Balsalazide Disodium Capsules 750 mg and Colazal® Capsules 750 mg
RandomizedCrossoverOpen-labelOther
Summary
The objective of this study was to investigate the bioequivalence of Mylan balsalazide disodium 750 mg capsules and Salix Colazal® 750 mg capsules following a single, oral 2250 mg (3 x 750 mg) dose administration under fasting conditions.
Timeline
- Start
- 2004-05
- Primary completion
- 2004-05
- Completion
- 2004-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balsalazide | Small molecule | 2250 mg | Oral |
Indications
No indication recorded.